加载中
HKSEHealthcareBiotechnology
最新数据
HK$3.80
−HK$0.20 · -5.00%
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
最新数据
HK$3.80
−HK$0.20 · -5.00%
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
52周区间
当前HK$3.80
历史价格可能经过调整并有所延迟。
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
52周区间
当前HK$3.80
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（HKD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3711.77万 HKD | 7791.83万 HKD | 7375.18万 HKD | 3737.91万 HKD | 1.07亿 HKD |
| 销货成本 | 290.02万 HKD | 1047.12万 HKD | 2192.58万 HKD | 1018.19万 HKD | 626.39万 HKD |
| 毛利 | 3365.16万 HKD | 6674.84万 HKD | 5182.6万 HKD | 2719.73万 HKD | 1亿 HKD |
| 研究与开发 | 9232.98万 HKD | 1.24亿 HKD | 1.4亿 HKD | 7012.06万 HKD | 1.4亿 HKD |
| 销售、一般及管理费用 | 4253.98万 HKD | 4450.23万 HKD | 1.54亿 HKD | 1.16亿 HKD | 3.28亿 HKD |
| 营业费用 | 1.84亿 HKD | 2.18亿 HKD | 2.93亿 HKD | 2.55亿 HKD | 5.12亿 HKD |
| 利息收入 | 510.09万 HKD | 516.89万 HKD | 1454.12万 HKD | 380.51万 HKD | — |
| 利息支出 | 10.28万 HKD | 11.92万 HKD | 6.31万 HKD | 8.09万 HKD | — |
| 折旧和摊销 | 1161.7万 HKD | 1053.6万 HKD | 1175.65万 HKD | 1196.09万 HKD | 1065.53万 HKD |
| 营业利润 | −1.51亿 HKD | −1.84亿 HKD | −2.41亿 HKD | −2.28亿 HKD | −4.11亿 HKD |
| 净利润 | −1.43亿 HKD | −1.56亿 HKD | −2.1亿 HKD | −1.83亿 HKD | −4.18亿 HKD |
公司数据更新于 2026年10月18日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
